Researchers are actively investigating these receptors as potential therapeutic targets for cancer treatment, and some clinical trials are exploring the use of drugs targeting Trk receptors to inhibit tumor growth in specific cancer types with aberrant NGF receptor expression. The gene discussed is NGFR; the disease is cancer.